Fidelity Investments
CLRB icon

Fidelity Investments’s Cellectar Biosciences CLRB Stock Holding History

Fidelity Investments’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$25 – 5595
2026
Q1 		$25 Buy
+10
New +$32 ﹤0.01% 5343
2024
Q1 		– Sell
-1
Closed -$50 – 5404
2023
Q4 		$50 Sell
1
-1
-50% -$74 ﹤0.01% 5015
2023
Q3 		$127 Hold
2
– – ﹤0.01% 4828
2023
Q2 		$96 Buy
+2
New +$96 ﹤0.01% 4963
2021
Q4 		– Hold
0
– – – 4392
2021
Q3 		– Hold
0
– – – 4414
2021
Q2 		– Hold
0
– – – 4309
2014
Q4 		– Sell
-3
Closed -$224K – 2795
2014
Q3 		$224K Buy
+3
New +$259K ﹤0.01% 2733

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Fidelity Investments's CLRB Position: Q2 2026 in Review

Fidelity Investments sold out of Cellectar Biosciences (CLRB) in Q2 2026, closing a stake of 10 shares — an estimated $25 sold.

Fidelity Investments first reported a position in CLRB in Q3 2014 and held it in 5 quarters. The position peaked at $224K in Q3 2014. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Fidelity Investments reported no remaining Cellectar Biosciences position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 10 Cellectar Biosciences shares in Q2 2026, an estimated $25.
  • Fidelity Investments first reported a position in Cellectar Biosciences in Q3 2014 and held it in 5 quarters.
  • Fidelity Investments's Cellectar Biosciences position peaked at $224K in Q3 2014.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.